Form 4: Cognition Therapeutics Chief Medical Officer Acquires 295,000 Shares in Stock Award

Chief Medical Officer Anthony Caggiano of Cognition Therapeutics Inc. reports acquiring 295,000 shares of common stock through a restricted stock unit (RSU) award, while also having shares withheld to cover tax obligations.

Summary

• On February 3, 2025, Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano had 12,779 shares of common stock withheld by the issuer to cover tax obligations related to the vesting of restricted stock units at a price of $0.666 per share.
• Following this transaction, Caggiano directly owned 128,850 shares.
• On February 4, 2025, Caggiano acquired 295,000 shares of Cognition Therapeutics Inc. common stock through restricted stock units (RSUs) at a price of $0.00.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• Following this acquisition, Caggiano directly owns 423,850 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by the CMO suggests confidence, but the tax withholding is a neutral event.

Positives

• The acquisition of 295,000 shares by the Chief Medical Officer could be seen as a positive sign, indicating confidence in the company's future prospects.

Negatives

• The withholding of 12,779 shares to cover tax obligations resulted in a decrease in the number of shares directly held.

Risks

• The value of the acquired shares is contingent upon the settlement of the RSUs, which are subject to certain conditions.
• Tax obligations arising from vesting RSUs can impact the net gain from equity compensation.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge management's sentiment and confidence in the company's performance and future prospects.

Stakeholder Impact

• Shareholders may view the acquisition of shares by the Chief Medical Officer as a positive signal.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates